SA515361055B1 - نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون - Google Patents

نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون

Info

Publication number
SA515361055B1
SA515361055B1 SA515361055A SA515361055A SA515361055B1 SA 515361055 B1 SA515361055 B1 SA 515361055B1 SA 515361055 A SA515361055 A SA 515361055A SA 515361055 A SA515361055 A SA 515361055A SA 515361055 B1 SA515361055 B1 SA 515361055B1
Authority
SA
Saudi Arabia
Prior art keywords
carrier particles
respirable agglomerates
micronized drug
porous carrier
drugs
Prior art date
Application number
SA515361055A
Other languages
English (en)
Inventor
تيونج باتريك
تارارا توماس
ويرس جيفري
هارتمان مايكل
Original Assignee
نوفارتيس ايه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by نوفارتيس ايه جي filed Critical نوفارتيس ايه جي
Publication of SA515361055B1 publication Critical patent/SA515361055B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بتجسيدات وفقا للاختراع الحالي توفر تركيبة مسحوق جاف تشتمل على جسيمات حاملة مسامية مرتبطة بواحد أو اثنين أو ثلاثة أو أكثر من العقاقير بحجم الميكرون أو APIs حيث ينتج خليط متناسق بين العقار أو العقاقير التي تكون بحجم الميكرون والجسيم الحامل، بحيث يلتصق العقار أو العقاقير التي تكون بحجم الميكرون بقوة بالجسيمات الحاملة التي تُكوّن خليط متناسق مستقر من نواتج تكتل قابلة للاستنشاق. تشتمل التجسيدات وفقا للاختراع الحالي كذلك على عملية إجراء التجفيف بالرش لتكوين نواتج التكتل القابلة للاستنشاق. تتعلق التجسيدات وفقا للاختراع الحالي كذلك باستخدام صيغة المسحوق الجاف التي تشتمل على نواتج تكتل قابلة للاستنشاق لعلاج مريض يعاني من مرض أو حالة يمكن علاجها بواسطة هذه الصيغة. الشكل 1 يمثل الاختراع
SA515361055A 2013-03-14 2015-09-13 نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون SA515361055B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784842P 2013-03-14 2013-03-14
PCT/IB2014/059739 WO2014141135A1 (en) 2013-03-14 2014-03-13 Respirable agglomerates of porous carrier particles and micronized drug

Publications (1)

Publication Number Publication Date
SA515361055B1 true SA515361055B1 (ar) 2016-11-13

Family

ID=50478894

Family Applications (1)

Application Number Title Priority Date Filing Date
SA515361055A SA515361055B1 (ar) 2013-03-14 2015-09-13 نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون

Country Status (22)

Country Link
US (2) US9452139B2 (ar)
EP (1) EP2968570A1 (ar)
JP (1) JP6374414B2 (ar)
KR (1) KR20150129716A (ar)
CN (1) CN105188757B (ar)
AU (2) AU2014229265A1 (ar)
BR (1) BR112015021814A2 (ar)
CA (1) CA2905615A1 (ar)
CL (1) CL2015002632A1 (ar)
EA (1) EA201591729A1 (ar)
GT (1) GT201500295A (ar)
HK (1) HK1212616A1 (ar)
IL (1) IL240963A (ar)
MA (1) MA38397A1 (ar)
MX (1) MX2015012814A (ar)
PE (1) PE20151655A1 (ar)
PH (1) PH12015501882A1 (ar)
SA (1) SA515361055B1 (ar)
SG (1) SG11201506397QA (ar)
TN (1) TN2015000395A1 (ar)
WO (1) WO2014141135A1 (ar)
ZA (1) ZA201505768B (ar)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1993360T3 (pl) 2005-12-28 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP3045452A1 (en) 2010-04-22 2016-07-20 Vertex Pharmaceuticals Inc. Process of producing cycloalkylcarboxamido-indole compounds
CN104955448A (zh) * 2013-01-31 2015-09-30 普罗索尼克斯有限公司 适用于吸入治疗的包含多组分结晶颗粒的药物组合物
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
CN106102724A (zh) * 2014-03-27 2016-11-09 诺华股份有限公司 用于吸入活性药物成分的经喷雾干燥的水包油包固体分散系
SG11201607670XA (en) 2014-04-15 2016-10-28 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2016142708A2 (en) * 2015-03-10 2016-09-15 Cipla Limited Pharmaceutical composition
US10423736B2 (en) * 2015-08-28 2019-09-24 University Of British Columbia Methods and systems for simulating hydrodynamics in gas-solid fluidized beds
EP3335699A1 (en) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US20200324064A1 (en) * 2019-04-10 2020-10-15 Cai Gu Huang Inhalation Device for Administering Powdered Pharmaceutical Composition
CN112804997B (zh) * 2019-06-03 2022-02-22 广州谷森制药有限公司 含马来酸茚达特罗和格隆溴铵溶液的可吸入制剂
US20220322724A1 (en) * 2019-08-15 2022-10-13 Abbott Laboratories Nutritional powder manufacturing process using micronization, and powder composition
IL297251A (en) * 2020-04-13 2022-12-01 Univ Basel lsd dose detection
CN114344285B (zh) * 2020-10-14 2023-11-14 江苏恒瑞医药股份有限公司 改良的可吸入团聚物
CN116546980A (zh) * 2020-12-11 2023-08-04 江苏恒瑞医药股份有限公司 用于肺部递送的药物组合物
CN113318097A (zh) * 2021-04-29 2021-08-31 珠海瑞思普利医药科技有限公司 一种抗特发性肺纤维化的粉雾剂及制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
SG43834A1 (en) 1991-06-26 1997-11-14 Schering Corp Inhalation device for powdered medicaments
SK282087B6 (sk) 1992-12-18 2001-10-08 Schering Corporation Inhalátor práškovitých liekov
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
JP3706136B2 (ja) 1994-09-21 2005-10-12 ネクター セラピューティクス 乾燥粉末薬剤の分散装置及び方法
CN1213974A (zh) 1996-01-03 1999-04-14 葛兰素集团有限公司 吸入器具
WO1997030743A2 (en) 1996-02-21 1997-08-28 Schering Corporation Powdered medication inhaler
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
CA2271276C (en) 1996-11-11 2009-01-13 Christian R. Noe Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
US20070212422A1 (en) 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
EP1283036B2 (de) 1998-11-13 2020-01-01 Jagotec AG Multidosis-Trockenpulverinhalator mit Pulverreservoir
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
WO2000072904A1 (en) 1999-05-28 2000-12-07 Inhale Therapeutic Systems, Inc. Apparatus and method for dispensing metered amount of aerosolized medication
US20010029947A1 (en) 1999-12-17 2001-10-18 Steve Paboojian Receptacles to facilitate the extraction of powders
US7069929B2 (en) 2000-02-01 2006-07-04 Quadrant Technologies Limited Dry powder inhaler
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
JP2006511617A (ja) 2002-12-13 2006-04-06 アダーギット 製薬用多孔質粒子
AU2004229446B2 (en) 2003-04-09 2010-02-25 Bgp Products Operations Gmbh Aerosolization apparatus with air inlet shield
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
RU2379062C2 (ru) 2004-02-24 2010-01-20 Майкродоуз Терапьютикс, Инк. Способ и устройство для доставки медикамента на основе синтезирующей струи
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
CN101479245B (zh) 2006-06-30 2013-05-22 诺瓦提斯公司 喹啉酮衍生物和其药物组合物
NZ576637A (en) 2006-10-25 2012-05-25 Novartis Ag Powder dispersion apparatus with and mediciment receptacles that are cut open using an elliptical arc shaped knife blade oriented to yaw between 4 and 12 degrees
RU2497524C2 (ru) 2008-05-15 2013-11-10 Новартис Аг Внутрилегочное введение флуорохинолона
EP2417106B1 (en) 2009-04-09 2016-11-30 Novartis AG Process for preparing pyrrolidinium salts
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JP5927175B2 (ja) 2010-04-01 2016-06-01 シエシー ファルマセウティチィ ソシエタ ペル アチオニ ドライパウダー状の吸入用医薬組成物、担体粒子および医薬品の製造方法
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug

Also Published As

Publication number Publication date
JP2016512494A (ja) 2016-04-28
US20160354388A1 (en) 2016-12-08
MX2015012814A (es) 2016-02-03
AU2017203258A1 (en) 2017-06-08
AU2017203258B2 (en) 2019-06-20
CN105188757B (zh) 2019-04-30
GT201500295A (es) 2017-09-28
WO2014141135A1 (en) 2014-09-18
PH12015501882A1 (en) 2015-12-07
JP6374414B2 (ja) 2018-08-15
TN2015000395A1 (en) 2017-01-03
ZA201505768B (en) 2017-03-29
IL240963A0 (en) 2015-11-30
CN105188757A (zh) 2015-12-23
CL2015002632A1 (es) 2016-03-28
US9744178B2 (en) 2017-08-29
US20140302147A1 (en) 2014-10-09
CA2905615A1 (en) 2014-09-18
KR20150129716A (ko) 2015-11-20
MA38397A1 (fr) 2018-01-31
AU2014229265A1 (en) 2015-09-03
SG11201506397QA (en) 2015-09-29
PE20151655A1 (es) 2015-11-26
IL240963A (en) 2017-05-29
BR112015021814A2 (pt) 2017-07-18
US9452139B2 (en) 2016-09-27
EA201591729A1 (ru) 2016-05-31
EP2968570A1 (en) 2016-01-20
HK1212616A1 (zh) 2016-06-17

Similar Documents

Publication Publication Date Title
SA515361055B1 (ar) نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون
SV2016005236A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
BR112015023629A2 (pt) formulação de acetato de abiraterona
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MX2015013845A (es) Polvos secos de tiotropio.
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
PH12016500118A1 (en) Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation
EA201791147A1 (ru) Фармацевтическая композиция, ее получение и применения
MX2015015150A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
IN2013MU01177A (ar)
MX2015012529A (es) Deamorfizacion de formulaciones secadas por pulverizacion a traves de pulverizacion de la mezcla.
MX2015011624A (es) Composiciones farmaceuticas secas que comprenden nanoparticulas de agente activo ligadas a particulas portadoras.
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
BR112017021111A2 (pt) processo para fabricação de misturas de pós secos
MX2017004633A (es) Formulaciones que contienen tiotropio, aminoacidos y acidos, y metodos de estas.
BR112017022855A2 (pt) combinação de dose fixa inviolável que provê liberação rápida de dois fármacos a partir de partículas e um pó
TH159392A (ar)
BR112017005523A2 (pt) formulações oculares para liberação de fármaco e proteção do segmento anterior do olho
TH173378A (th) "สูตรผสมคอมโพสิตสำหรับใช้ทางปากที่ประกอบรวมด้วยเอเซทิมิเบ และโรซูวาสทาทิน"
NZ712318A (en) Coated phenylephrine particles and use thereof in pharmaceutical formulations